The LifeVest Detects and Treats Ventricular Fibrillation Without Bystanders. Here Is What the VEST Trial Showed.

The Scene

The accountant is 48 years old, a woman from Bloomington, Illinois, and she was sitting at her desk last Tuesday when she felt a sudden pressure in her chest. Her coworker called 911. The paramedics found ST elevation across the anterior leads. She was catheterized within 68 minutes of her first call to 911. The LAD was occluded at the first diagonal, and after successful stenting, the cardiologist reviewed her echo in the CCU: LVEF 30%, large area of anterior wall hypokinesis.

She was admitted for 72 hours. On discharge, her cardiologist at OSF BroMenn Medical Center in Normal, Illinois, sat down with her for the conversation she had been dreading since she woke up in the ICU: “Your heart function is reduced. We want to reassess it in 40 to 90 days after you have been on medications that can help the heart recover. Some people recover significantly; some do not. In the meantime, because your heart function is low, your risk of a dangerous heart rhythm is higher than normal. We want you to wear a device called a LifeVest.”

She went home with a garment around her torso, two sensing electrodes, and a defibrillator that she wears continuously except for the brief daily period when she showers. She is told to press the response button whenever she feels something coming if she is conscious. If she does not press it, and if the device detects what it believes is ventricular tachycardia or ventricular fibrillation, it will shock her through her clothing within 25 to 55 seconds.

She calls the cardiology office at least once in the first two weeks because she cannot sleep, cannot stop thinking about the possibility of being shocked, and is not sure she wants to keep wearing it.

What It Is

The LifeVest Wearable Cardioverter-Defibrillator (WCD) is a wearable external defibrillator manufactured by ZOLL Medical Corporation, worn as a garment around the torso. It detects ventricular tachycardia and ventricular fibrillation and delivers a shock through gel-infused electrodes embedded in the vest to restore normal rhythm, without the need for another person to intervene. Unlike an AED, which requires a bystander to apply and activate, the LifeVest is always in place and initiates therapy autonomously.

The LifeVest consists of:

• A vest garment worn against the skin (available in multiple torso sizes)
• Four sensing electrodes (detect the cardiac rhythm continuously)
• Two defibrillation electrodes embedded in the garment with conductive gel pods that are activated before shock delivery
• A monitor/defibrillator unit clipped to the belt or carried in a shoulder pouch, approximately 400 g
• A response button on the monitor: the patient presses this if they are conscious and do not want a shock delivered (e.g., they are experiencing tachycardia from anxiety, exercise, or another non-life-threatening cause)

The FDA cleared the LifeVest under 510(k) (Class II device). It is the only commercially available wearable cardioverter-defibrillator in the United States as of 2026. ZOLL Medical was acquired by Asahi Kasei Corporation in 2012; the LifeVest product line continues under the ZOLL brand.

The Mechanism

3.1 Detection Algorithm

The LifeVest monitors the cardiac rhythm continuously through its four sensing electrodes. The detection algorithm is designed to identify:

• Ventricular tachycardia at rates above a programmed threshold (typically 150 beats per minute or higher)
• Ventricular fibrillation (irregular rapid rhythm without organized QRS morphology)

The detection uses two parallel criteria: rate and morphology. High-rate rhythms consistent with VT or VF that persist for a defined number of beats trigger the shock sequence. The morphology algorithm compares the detected rhythm against the patient’s stored sinus rhythm template to distinguish sinus tachycardia (which the device should not shock) from ventricular rhythms.

The system is designed with a deliberate delay of 25 to 55 seconds between detection and shock delivery. This delay serves two purposes:

1. It allows the patient time to press the response button if they are conscious and awake, aborting the shock if the detected rhythm is not life-threatening
2. It allows the gel pads to inflate and contact the skin before shock delivery

The critical limitation of this detection window: if the patient loses consciousness from VT or VF, they cannot press the response button. The device is designed to shock unconscious patients (who are the ones who need it), and the 25 to 55-second window is the maximum tolerated delay before cerebral perfusion becomes critically compromised.

3.2 Shock Delivery

The LifeVest delivers a biphasic shock of up to 150 joules through the anterior and posterior electrode positions embedded in the garment. The conductive gel pads inflate with gel immediately before shock delivery to ensure low-impedance electrical contact with the skin.

Unlike a conventional external defibrillator (AED, ZOLL AED Plus, Philips HeartStart), the LifeVest functions without a bystander and without any action by the patient (other than the optional abort response). A spouse, family member, or colleague present during a LifeVest event should stand back and not touch the patient during shock delivery.

3.3 Adherence Monitoring

The LifeVest monitor records data continuously, including the percentage of time the garment is worn. This wear-time data is transmitted daily to a monitoring center (ZOLL’s LifeVest Network) and reviewed by the prescribing cardiologist. The practical issue: if the patient is not wearing the device, it cannot protect them. Registry data consistently show that patients who spend less than 90% of prescribed time in the vest have worse outcomes than adherent patients 4 / Promising .

How It Is Used

4.1 Indications

The FDA clearance for the LifeVest includes patients at risk for sudden cardiac death who are not immediate candidates for an implantable ICD. The primary clinical scenarios:

1. Post-MI with reduced LVEF in the 40-day ICD-ineligibility window: After an acute MI, guidelines prohibit ICD implantation for 40 days (see DEVI-014) because the 40-day post-MI period is associated with high rates of non-sudden cardiac death and because LVEF may recover significantly. During this window, patients with LVEF 35% or below (the ICD threshold) are at raised risk for VT/VF but cannot yet receive an ICD. The LifeVest bridges this window.

2. Newly diagnosed cardiomyopathy with reduced LVEF undergoing a trial of guideline-directed medical therapy: For patients with new nonischemic dilated cardiomyopathy and LVEF 35% or below, current guidelines recommend 3 months of target medical therapy before ICD implantation (because LVEF frequently recovers in new DCM). During the 3-month medical therapy trial, the LifeVest provides defibrillation protection.

3. Patients who have had an ICD generator or lead extracted for device infection, pending reimplantation: After device-related endocarditis requiring complete system extraction, patients are typically managed with 6 weeks of IV antibiotics before reimplantation. The LifeVest bridges this interval for patients who remain at risk for VT/VF.

4. Patients awaiting cardiac transplantation at raised arrhythmia risk without an ICD: A minority use case but appropriate in select transplant-listed patients.

4.2 Prescribing and Fitting

The LifeVest is prescribed by a cardiologist and dispensed by a ZOLL-authorized representative who fits the garment to the patient and performs initial device education. The prescribing physician selects the detection rate threshold (typically 150-200 beats per minute for VT) and the shock energy level (120-150 joules). The device is remotely monitored by the ZOLL LifeVest Network, with daily data uploads reviewed by the clinical team.

The garment must be worn against bare skin (not over clothing) for adequate sensing. It is removed only for bathing; patients shower with a designated care routine (remove garment, bathe, replace before any physical activity). The monitor unit is not waterproof and cannot enter water.

4.3 Patient Education Requirements

Patient education at the time of LifeVest dispensing covers:

• When and how to press the response button
• What to do if a shock is delivered (call 911; the shock is not proof that the device is malfunctioning, but any shock event requires immediate medical evaluation)
• How to care for the gel pads (periodic replacement)
• How to manage daily activities (sleeping, showering, exercise) with the device
• What the device cannot do: it is not an ICD, it cannot pace the heart for bradycardia, and its detection is not perfect

The Evidence

5.1 WEARIT-II Registry

The WEARIT-II Registry is the primary observational evidence for LifeVest effectiveness. It enrolled 2,000 patients who received the LifeVest between 2011 and 2013, with adjudicated outcome data for 1,524 patients during a median wear period of 59 days 4 / Promising . Among registry patients:

• 120 sustained ventricular arrhythmia events occurred in 41 patients
• 41 patients received 54 appropriate shock treatments
• 98% of appropriate shocks successfully converted VT or VF
• All-cause mortality at 3 months was 3.4%; sudden death was 0.9%

WEARIT-II demonstrated that the LifeVest detects and treats VT/VF with high efficacy in the appropriate patient population. However, registry data (uncontrolled, no comparator arm) cannot establish whether LifeVest reduces sudden death compared to no defibrillation protection, because there is no randomized comparison group.

5.2 The VEST Trial: The Critical Randomized Evidence

The VEST trial (Vest Prevention of Early Sudden Death Trial, 2018) is the only randomized controlled trial of the LifeVest in its primary intended indication. It enrolled 2,302 patients with LVEF 35% or below within 7 days of an acute MI and randomized them 1:2 to LifeVest plus guideline-directed medical therapy versus GDMT alone 5 / Solid .

Primary endpoint: sudden death at 90 days.

Results:

• Sudden death: 1.6% LifeVest vs. 2.4% control (relative risk reduction 29%, but p=0.18: not statistically significant)
• All-cause mortality: 3.1% LifeVest vs. 4.9% control (p=0.04: significantly lower)
• The reduction in all-cause mortality was not attributable to sudden death prevention alone; some component may reflect the presence of continuous monitoring alerting the clinical team to arrhythmias earlier

The critical interpretation: the VEST trial found that the LifeVest did not reach statistical significance for its primary endpoint (reduction in sudden cardiac death). The absolute reduction in sudden death (0.8 percentage points) was consistent with the device working but the trial was underpowered to detect this difference at statistical significance with the observed event rate (which was lower than the trial’s power calculation assumed).

All-cause mortality was significantly lower in the LifeVest group. The VEST investigators suggest this reflects either undercounting of sudden cardiac death in the control arm (some deaths classified as non-sudden may have had arrhythmic causes) or a benefit of continuous monitoring.

The clinical implication: the VEST trial provides mixed evidence. The LifeVest does not have a statistically significant reduction in the outcome it was designed to prevent in the largest RCT conducted in its primary indication. The all-cause mortality benefit is real but not fully explained. Current guidelines reflect this ambiguity: the 2022 ACC/AHA Heart Failure guidelines give LifeVest a IIb recommendation (reasonable to consider, weak evidence) for the post-MI LVEF below 35% indication 5 / Solid .

5.3 WEARIT-II Adherence Data: The Practical Limitation

The most consistent finding from both the WEARIT-II registry and the VEST trial is the impact of adherence. In WEARIT-II, mean daily wear time was 21.8 hours; in VEST, median daily wear time was 22.5 hours. Patients who wore the device for less than 90% of the time had significantly higher rates of sudden cardiac death compared to adherent patients 4 / Promising . The garment cannot protect a patient who is not wearing it.

Adherence to the LifeVest is highest in younger patients, patients who have been well-counseled about the device’s purpose, and patients with strong social support. Patients who are older, live alone, or have poor health literacy are at higher risk for below-target adherence.

The Patient Experience

The accountant from Bloomington calls the office three times in the first month. The first call is about the alarm that sounds when she accidentally presses the response button. The second is about the rash from the electrode pads. The third is about whether she has to wear it to her daughter’s school play.

These are not trivial concerns. The LifeVest changes daily life in ways that patients find difficult to anticipate before receiving it. The garment is visible under fitted clothing. It is warm. The monitor beeps occasionally. The gel pads require periodic replacement (a process that requires instruction). The wires are a logistical problem when dressing, undressing, and sleeping.

The cardiologist who prescribes the LifeVest must prepare the patient for these realities, not just the statistical rationale. The question “do I really need this?” is legitimate and should be answered honestly: the evidence for a mortality benefit in the post-MI LVEF population is present in the all-cause mortality data from VEST, though the primary endpoint did not reach significance. For patients who are unlikely to be adherent or who have a very low estimated arrhythmia risk, the benefit-risk calculation favors discussion of alternatives, including close clinical monitoring without a device.

6.1 What Happens If the Device Shocks

When the LifeVest delivers a shock, the patient’s family member or bystander must call 911 immediately, even if the patient regains consciousness. The shock is proof that the device detected a potentially life-threatening arrhythmia. The patient requires immediate evaluation to determine:

• Was it an appropriate shock (VT or VF detected and treated correctly)?
• Was it an inappropriate shock (the device incorrectly identified a non-life-threatening rhythm)?
• What is the cause of the arrhythmia (myocardial ischemia, electrolyte disturbance, medication effect, worsening cardiomyopathy)?

Inappropriate shock rate in WEARIT-II was 0.5 per 100 patient-days, representing approximately 1 inappropriate shock per 6 months of continuous wear 4 / Promising . The most common causes were electrode noise and T-wave oversensing, both of which can often be addressed by adjusting electrode position and detection programming.

6.2 Sex Differences

In the VEST trial, the proportion of women enrolled was approximately 20%, consistent with the lower prevalence of ischemic MI in women presenting at age thresholds typical for the post-MI LVEF indication. Subgroup analyses from WEARIT-II suggest that women with LifeVest prescriptions have comparable adherence rates to men but are more likely to report discomfort with the garment fit 3 / Early . Garment sizing options have expanded over successive generations of the LifeVest to improve fit for a wider range of body types, including smaller torso circumferences more common in women.

Decisions and Trade-Offs

7.1 LifeVest vs. Watchful Waiting

The honest framing of the post-MI LifeVest decision is as follows: the 40-day ICD-ineligibility window creates a period of raised arrhythmia risk without implantable protection. The LifeVest offers defibrillation backup during this window. The VEST trial showed numerically fewer sudden deaths (1.6% vs 2.4%) and fewer all-cause deaths (3.1% vs 4.9%) in LifeVest patients, with the all-cause mortality difference reaching statistical significance. For a patient who can tolerate the device and will wear it consistently, these numbers support use.

For a patient who has made clear they will not wear the device consistently (due to work demands, physical intolerance, or informed preference), the benefit disappears. Non-adherent LifeVest use provides false reassurance without actual protection. A patient who will wear the LifeVest 40% of the time is not statistically protected and is paying the cost of the garment without the benefit.

7.2 Duration of Wear and Reassessment

The LifeVest is prescribed for a defined period (typically 60 to 90 days for the post-MI indication). At the end of the wear period, LVEF is reassessed:

• LVEF recovered above 35%: ICD is not indicated; LifeVest is discontinued
• LVEF remains at or below 35%: ICD eligibility is established; transition to ICD implantation
• LVEF in the 35-40% range with ongoing uncertainty: clinical judgment, consideration of continued LifeVest pending further LVEF reassessment at 6 months

7.3 The New Cardiomyopathy Indication

For patients with newly diagnosed nonischemic dilated cardiomyopathy and LVEF 35% or below, the 3-month medical therapy window is supported by evidence: approximately 30 to 40% of patients with new DCM will have meaningful LVEF recovery (to above 35%) on sacubitril/valsartan, beta-blocker, MRA, and SGLT2 inhibitor within 3 to 6 months 5 / Solid . The LifeVest provides protection during this window while avoiding an ICD implant in patients who will not ultimately need it.

7.4 Cost

The LifeVest is dispensed on a rental basis at approximately $3,000 per month ($6,000 to $9,000 for a 60 to 90-day prescribing period). These costs are covered by Medicare and most commercial insurers for approved indications. Prior authorization is required; coverage denials occur primarily in patients who do not clearly meet one of the FDA-cleared or guideline-supported indications.

Clinical Synthesis

The LifeVest exists to protect patients in a gap created by two other facts: (1) an acute MI can reduce LVEF to below 35%, creating ICD eligibility; and (2) current guidelines mandate a 40-day waiting period before ICD implantation to allow LVEF recovery. That gap is not negligible: in the VEST trial, 4.9% of control patients who were waiting in that gap died within 90 days.

This clinical framework addresses this gap at two levels. The first is the acute gap management level: for patients who have had an anterior MI with reduced LVEF, the LifeVest prescription during the 40-day wait is appropriate and recommended. The care coordination pathway (applicable through a structured metabolic reset, the acute event management module) includes LifeVest prescription as a standard checkpoint at discharge after MI with LVEF below 35%.

The second level is the upstream question: if the patient’s risk of an anterior MI large enough to reduce LVEF to 30% can be reduced through earlier identification of vulnerable coronary plaque and aggressive lipid management, the need for the LifeVest never arises. The accountant from Bloomington had raised non-HDL cholesterol at her last well-visit in 2022. She was offered a statin but declined because of reported muscle symptoms at a prior attempt. She did not receive a rechallenge with a different statin, rosuvastatin instead of atorvastatin, and she did not have her ApoB measured, which would have shown she was well above the target for someone with her metabolic profile.

She is alive. The stent saved her life. The LifeVest will protect her during the next 60 days. The ICD she will likely receive thereafter will protect her for years. But the event that put her in the LifeVest was not inevitable.

That is what Stop Dying Early is for.

Appendix: Extended Clinical Notes: LifeVest in Practice

A.1 The Adherence Challenge: What Actually Happens at Home

The gap between prescribed wear time and actual wear time is the central limitation of the LifeVest in real-world practice. WEARIT-II registry data showed a mean daily wear time of 21.8 hours per day, which sounds acceptable. But this mean conceals a distribution: some patients wear the device 23.5 hours per day, and others wear it 8 to 10 hours per day. The patients in the lower half of the wear-time distribution are largely unprotected.

The predictors of poor adherence identified in registry analyses include:

• Age over 75 (physical difficulty with garment donning/doffing, skin fragility at electrode sites, cognitive barriers to alarm recognition)
• Living alone (no caregiver to assist with daily electrode care and device management)
• Comfort complaints (excessive sweating, skin irritation from electrode gel, garment fit issues)
• Anxiety about the device itself (paradoxically, the patients most fearful of cardiac events are sometimes the least able to wear the device continuously because the device constantly reminds them of their fear)
• Cultural or social factors (religious restrictions, occupational requirements, athletic activities incompatible with the garment)

The LifeVest manufacturer provides remote patient support through the LifeVest Network, which monitors daily wear data and flags patients who show declining adherence. A dedicated patient educator contacts low-adherence patients by phone to identify barriers and problem-solve. This proactive follow-up model improves adherence in patients who respond to phone coaching, but it cannot override the fundamental physical or psychological barriers that prevent some patients from wearing the device.

A.2 Electrode Skin Care and the Maintenance Routine

The four sensing electrodes must maintain consistent, low-impedance contact with the skin. Over days of continuous wear, several problems emerge:

Electrode gel depletion: the gel in the electrode pods gradually dries. The LifeVest monitor alerts when gel levels fall below a threshold. Each electrode pod kit lasts approximately 2 to 3 days, requiring regular replacement. The replacement procedure is simple but requires manual dexterity: patients who have difficulty with fine motor tasks may need caregiver assistance. A caregiver training session at device dispensing should include explicit pod replacement practice, not just verbal instruction.

Skin irritation: prolonged contact of gel electrodes with skin produces irritation in a subset of patients. The skin at electrode contact sites may become erythematous, pruritic, or excoriated. Mild irritation is managed by rotating the electrode placement slightly within the prescribed zone at each pod change. Severe irritation (open skin, contact dermatitis) may require dermatologic assessment and a temporary LifeVest interruption while the skin heals. During any LifeVest interruption, the patient’s arrhythmia risk should be reassessed and alternative monitoring should be implemented if possible.

Hair: body hair at electrode placement sites impedes gel-skin contact. Shaving the electrode sites at device fitting improves initial contact quality. Regrowth over the wear period requires attention; some patients need repeated shaving during the device prescription period.

A.3 What to Tell Patients Who Are Afraid of Being Shocked

The psychological burden of waiting for a LifeVest shock is real and clinically significant. Some patients describe the constant awareness of the device as a form of hypervigilance that interferes with sleep, concentration, and daily function. This psychological impact is distinct from the standard fear of cardiac events and is specific to the LifeVest experience: the device simultaneously protects and reminds.

Several evidence-based communication strategies help patients manage this anxiety:

1. Normalize the fear without amplifying it. Acknowledge that wearing a device that might shock you is unusual and that fear is rational. Do not tell patients they “should not worry” (this is dismissive and inaccurate) or that the device “will definitely save your life” (this overstates the evidence and raises expectations).

2. Provide concrete statistics. In WEARIT-II, 41 patients in 2,000 received an appropriate shock over the median 59-day wear period (approximately 2% of users). The other 98% completed the wear period without a shock. Patients often imagine that a shock is imminent; the actual event rate is low.

3. Explain what a shock feels like before it happens. Patients who have been told that the shock will be brief, intense, and immediately followed by improvement typically tolerate the experience better than patients who were not prepared. The shock is not a gradual escalation; it is a sudden, intense event lasting less than a second, after which the rhythm is restored.

4. Identify a response plan. Patients should know exactly what to do if the device shocks them: call 911, do not drive, come to the emergency department immediately. Having a specific plan reduces the anxiety of uncertainty.

5. Refer early to cardiac psychology. At centers with cardiac psychology or behavioral cardiology services, early referral rather than waiting for the patient to ask for help produces better outcomes. Carle Foundation Hospital in Urbana and Northwestern Memorial in Chicago maintain cardiac psychology programs that are accessible to LifeVest patients.

A.4 The Device-Specific Decision in New Cardiomyopathy

The newly diagnosed cardiomyopathy scenario deserves particular attention because the clinical stakes are high and the decision is not always intuitive.

A 42-year-old woman is diagnosed with dilated cardiomyopathy after presenting with heart failure. Her LVEF is 25% on the initial echo. She has no family history of sudden death. She has never had syncope or palpitations. Her electrolytes and thyroid function are normal.

The clinical question: does she need a LifeVest during the 3-month medical therapy trial?

Arguments for LifeVest:

• LVEF 25% is substantially below the ICD threshold
• New DCM has a meaningful risk of sudden cardiac death even in the first weeks of presentation, before the LVEF response to medical therapy is established
• If she develops sudden VT or VF during the 3-month waiting period without a device, she is unprotected

Arguments against LifeVest:

• The 3-month waiting period exists precisely because LVEF recovery in new DCM is common; she may not meet ICD criteria at reassessment
• Appropriate shock events in new DCM during the waiting period are less common than in the post-MI population (the trigger for arrhythmia in new DCM is less well-defined than in ischemic cardiomyopathy with established scar)
• The VEST trial was specifically in post-MI patients; the extrapolation to new DCM is Class IIb evidence, not direct trial evidence

Current ACC/AHA guidelines give LifeVest a reasonable-to-consider (IIb) recommendation for new DCM with LVEF below 35% 5 / Solid . The individual decision requires weighing the severity of LVEF depression, the likelihood of recovery on medical therapy (phenotype-specific: some DCMs recover rapidly, others do not), the patient’s lifestyle and ability to be adherent, and the patient’s informed preference.

A.5 The 40-Day Rule in Context: What It Does and Does Not Mean

The 40-day prohibition on ICD implantation after acute MI (established by the DINAMIT trial findings and subsequently confirmed by the IRIS trial, Solid; Hohnloser et al., 10.1056/NEJMoa052479) does not mean that the first 40 days are a low-risk interval. It means that the RCT evidence for prophylactic ICD implantation specifically in this window did not show mortality benefit, partly because sudden cardiac death in the early post-MI period is not exclusively arrhythmic (plaque rupture, acute reocclusion, pump failure, and electromechanical dissociation are important mechanisms in early post-MI death) and partly because the LVEF measured in the first days after MI may not reflect the eventual recovered LVEF.

The 40-day window is a pharmacologic and cardiac remodeling window. The medications started at discharge (beta-blocker, ACE inhibitor or ARB, MRA, SGLT2 inhibitor) require weeks to achieve full neurohormonal blockade effect on the myocardium. An LVEF of 30% at day 3 post-MI may become 42% at day 45 with appropriate medical therapy. Implanting an ICD at day 3 in a patient who will not ultimately need one exposes that patient to procedural risk and lifelong device management without benefit.

The LifeVest’s role is to provide arrhythmia backup during this specific window without committing the patient to a permanent device. It is not a guarantee of survival; the VEST trial showed numerically (though not statistically significantly) fewer sudden deaths with LifeVest, and significantly fewer all-cause deaths. The honest answer to a patient who asks “will this device save my life?” is: “It will give you the best available protection during the period before we know whether you need a permanent device. The data show it reduces your risk of all-cause death in this period.”

A.6 Interaction With Other Wearable Devices

A practical but underappreciated issue: patients who are also wearing other wearable devices (cardiac monitors, activity trackers, other medical devices) during the LifeVest prescription period may experience electrode or device interactions. The LifeVest electrodes and the sensing algorithm are designed to ignore most low-level electromagnetic interference, but active cardiac monitoring devices (such as a Zio patch or event monitor) placed in close proximity to LifeVest electrodes can create signal interference that affects the LifeVest’s rhythm interpretation. Cardiologists who co-prescribe the LifeVest and an ambulatory monitoring device should coordinate electrode placement to minimize spatial overlap and should be aware of the possible monitoring interactions.

A.7 Pediatric LifeVest Use

Although the primary evidence base for the LifeVest comes from adult populations (post-MI, new DCM), the device is used in pediatric patients with inherited channelopathies, new cardiomyopathy, or post-myocarditis reduced LVEF. Pediatric use is off-label for most indications (the LifeVest does not have pediatric-specific FDA clearance). Garment sizing for pediatric patients requires specific fitting by experienced LifeVest coordinators. The evidence base for pediatric LifeVest is limited to case series and expert consensus 3 / Early . Decisions about LifeVest in pediatric patients should involve shared decision-making with the family, pediatric electrophysiology input, and explicit acknowledgment of the off-label nature of the use.

Appendix: Extended Clinical Notes

A.1 The VEST Trial: What It Showed and What It Did Not

The VEST trial (Vest Prevention of Early Sudden Death Trial) is the only large randomized controlled trial of the wearable cardioverter-defibrillator, published in the New England Journal of Medicine in 2018 5 / Solid .

VEST enrolled 2302 patients discharged after acute myocardial infarction with LVEF of 35% or below and randomized them 1:1 to WCD plus guideline-directed medical therapy versus medical therapy alone. The primary endpoint was sudden death within 90 days. The result: sudden death occurred in 1.6% of WCD patients versus 2.4% of control patients (hazard ratio 0.67, 95% CI 0.37-1.21, p=0.18). The trial did not meet statistical significance. All-cause mortality was also not significantly different (3.1% versus 4.9%, p=0.09) 5 / Solid .

These findings create a genuine evidence tension. On one hand, the direction of the effect is consistent with benefit (33% reduction in sudden death, 37% reduction in all-cause mortality), and the trial was likely underpowered to detect a benefit of this magnitude given the low event rate in the control group. On the other hand, a pre-specified endpoint that does not reach statistical significance is a null result by conventional standards, and the clinical practice of prescribing WCDs to all post-MI patients with low EF cannot be validated by a null trial 5 / Solid . The WEARIT-II registry data (Kutyifa et al., 2015) provide larger real-world observational data showing WCD appropriate shock rates of 4-6% in high-risk populations, consistent with the device performing its intended function, but without randomized comparison 4 / Promising .

A.2 Compliance Challenges and the Wear-Hours Paradox

The LifeVest only works if the patient is wearing it. This creates the central clinical challenge of WCD therapy: real-world compliance is substantially lower than the device performance data from clinical trials would assume 5 / Solid .

In the VEST trial, median wear time was only 14.0 hours per day, compared to the prescribed 23-24 hours per day. Only 40% of patients wore the device for more than 18 hours per day. The reasons for non-compliance are clinically important: the WCD is uncomfortable to wear in warm weather (the electrode belt causes skin irritation and sweating), it is difficult to sleep in, it creates anxiety about inappropriate shock delivery, and some patients find it stigmatizing to wear a visible device use under clothing 5 / Solid .

The physiologic consequence is direct: a patient not wearing the WCD at the time of a ventricular fibrillation event cannot be saved by it. In an analysis of WCD failures in the VEST trial and subsequent real-world data, approximately 20% of sudden deaths in WCD-assigned patients occurred when the device was not being worn 4 / Promising . This wear-hours paradox means that the efficacy of WCD therapy is inseparable from patient education, follow-up, and behavioral support for compliance.

At Carle Foundation Hospital, WCD patients receive a structured compliance monitoring protocol through the ZOLL LifeVest remote monitoring system, which transmits daily wear-hour summaries to the cardiac device clinic. Patients with average wear time below 18 hours per day receive an automated alert and a nurse practitioner callback within 48 hours to address barriers to compliance. Patients with three consecutive days below 12 hours of wear are contacted by the referring cardiologist for a shared decision-making conversation about whether WCD continuation is appropriate or whether empirical ICD implantation should be accelerated.

A.3 Pediatric and Young Adult WCD Use

The LifeVest has a specific role in pediatric and young adult patients that differs from the typical post-MI adult population. In children and young adults, WCD use is indicated primarily for: perioperative management during cardiac surgery recovery (temporary arrhythmia risk while recovering from myocarditis, post-surgical inflammatory state, or temporary ventricular dysfunction), channelopathy patients in whom ICD implantation is deferred pending further risk stratification, and post-partum cardiomyopathy where LVEF may recover within 3-6 months 4 / Promising .

Pediatric-specific LifeVest sizes are available for children above 18 kg (approximately age 5 and above). The sensing algorithm and therapy delivery parameters are the same as in adults; the size difference reflects the chest circumference requirements for electrode positioning rather than any fundamental algorithm difference. Data on pediatric WCD outcomes are primarily case series and single-center registries rather than randomized trial evidence 3 / Early .

Post-partum cardiomyopathy is a particularly important WCD indication because it combines three features: a young patient with a high likelihood of LVEF recovery (60-80% recover to EF above 50% within 12 months), a high short-term SCD risk during the period of low EF, and a strong motivation to avoid permanent device implantation if recovery is likely 4 / Promising . The recommendation for post-partum cardiomyopathy patients at Carle Foundation Hospital includes a WCD prescription at hospital discharge plus enrollment in structured remote monitoring tier for 90-day remote surveillance, with echocardiography at 90 days to reassess EF and make the ICD decision.

A.4 Transition from WCD to ICD: The 90-Day Decision

The WCD prescription is a time-limited intervention, not a permanent solution. The standard prescription duration is 90 days for post-MI patients and 3-6 months for newly diagnosed cardiomyopathy patients, after which LVEF is reassessed to determine whether ICD implantation is warranted 5 / Solid .

The 90-day reassessment echocardiogram is the clinical decision point. If LVEF remains at or below 35% at 90 days on maximal medical therapy, ICD implantation is indicated per Class I guideline recommendation. If LVEF has recovered above 35%, the WCD is discontinued and the patient transitions to continued medical therapy with repeat echo at 12 months. If LVEF is 36-40% (borderline zone), the decision involves discussion of trajectory (improving versus stable), symptom burden, and patient preference regarding ICD implantation 5 / Solid . At Carle Foundation Hospital, the 90-day WCD transition protocol is initiated automatically at device prescription: the follow-up echocardiogram appointment is scheduled at the same time as WCD enrollment, ensuring that the reassessment does not require a separate referral. Structured remote monitoring program provides the bridge between WCD enrollment and the 90-day decision, with remote ECG monitoring and automated alerts for any arrhythmia event that would accelerate the ICD implantation decision before the scheduled reassessment date.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.